Kernalbio develops mRNA therapies that enable selective translation of therapeutic proteins in target cells, utilizing a clinically validated delivery system to enhance tissue specificity. This approach addresses the limitations of traditional mRNA design, which often fails to effectively target specific cells within tissue and tumor microenvironments.
Funding
$25M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+7Founders
Product
Problem
Traditional mRNA therapies often lack precise targeting of specific cells within tissues and tumor microenvironments, leading to off-target effects and reduced efficacy. This inability to selectively translate therapeutic proteins in desired cells limits the therapeutic potential of mRNA-based treatments.
Solution
Kernalbio develops mRNA therapies that enable selective translation of therapeutic proteins specifically within target cells. Their approach utilizes a clinically validated delivery system to enhance tissue specificity, ensuring the mRNA is delivered to the intended location. By programming mRNAs that are selectively translated, Kernalbio aims to create a novel class of therapies with improved efficacy and tolerability compared to standard treatments. This targeted approach overcomes the limitations of conventional mRNA designs, which often struggle to achieve precise cell selection within complex tissue environments.
Target Audience
The primary target audience includes patients with diseases that can be treated with targeted protein expression, and pharmaceutical companies developing mRNA-based therapeutics.
Features
- mRNA design for selective translation of therapeutic proteins in target cells.
- Clinically validated delivery system for enhanced tissue specificity.